Apyx Medical (APYX) to Release Quarterly Earnings on Thursday

Apyx Medical (NASDAQ:APYX) is projected to announce its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 8:00 AM ET.

Apyx Medical Stock Performance

NASDAQ APYX opened at $3.30 on Thursday. The company has a quick ratio of 3.61, a current ratio of 4.44 and a debt-to-equity ratio of 5.69. Apyx Medical has a fifty-two week low of $0.76 and a fifty-two week high of $4.50. The business has a fifty day moving average of $3.75 and a 200-day moving average of $3.27. The stock has a market cap of $126.19 million, a price-to-earnings ratio of -9.17 and a beta of 1.61.

Analyst Ratings Changes

Several research analysts recently weighed in on APYX shares. Wall Street Zen raised shares of Apyx Medical to a “hold” rating in a research note on Saturday, November 22nd. Zacks Research raised shares of Apyx Medical to a “hold” rating in a research report on Wednesday, December 17th. Citizens Jmp upgraded shares of Apyx Medical from a “market perform” rating to an “outperform” rating and set a $8.00 target price on the stock in a research report on Wednesday, November 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Apyx Medical in a report on Monday, December 29th. Finally, Roth Mkm initiated coverage on Apyx Medical in a research note on Monday, December 15th. They set a “buy” rating and a $6.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Institutional Investors Weigh In On Apyx Medical

A number of institutional investors have recently bought and sold shares of the stock. Citadel Advisors LLC purchased a new position in shares of Apyx Medical in the 3rd quarter valued at $28,000. Osaic Holdings Inc. purchased a new position in Apyx Medical in the second quarter valued at about $50,000. Franklin Resources Inc. acquired a new position in shares of Apyx Medical during the third quarter worth about $59,000. Hudson Bay Capital Management LP purchased a new stake in shares of Apyx Medical in the fourth quarter worth about $73,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in shares of Apyx Medical in the fourth quarter worth about $111,000. 55.33% of the stock is currently owned by hedge funds and other institutional investors.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.